View Older Stories View More Recent Stories

Jul 26, 2023 08:00AM Intercept to Announce Second Quarter 2023 Financial Results on August 2, 2023
Jul 24, 2023 06:00AM Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
Jun 23, 2023 06:30AM Intercept Pharma (ICPT) Announces Restructuring
Jun 23, 2023 06:30AM Intercept Announces Restructuring to Strengthen Focus on Rare and Serious Liver Diseases and Significantly Reduce Operating Expenses
Jun 23, 2023 02:45AM Intercept Presents New Data Showing Significant Impact of OCA-bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage
Jun 22, 2023 05:52PM Intercept Pharma (ICPT) Receives CRL for Obeticholic Acid
Jun 22, 2023 05:45PM Intercept Receives Complete Response Letter from FDA for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
Jun 7, 2023 07:01AM Intercept Pharma (ICPT) Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC
Jun 7, 2023 07:00AM Intercept Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023
May 31, 2023 08:00AM Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Jefferies Healthcare Conference June 7-8, 2023
May 20, 2023 07:32AM Intercept Pharma (ICPT) Announces Vote Not Favoring Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
May 19, 2023 06:45PM Intercept Announces Outcome of FDA Advisory Committee Meeting for Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
May 19, 2023 07:06AM Intercept (ICPT) Confirms Stock Trading Halted Ahead of FDA Advisory Committee to Review Obeticholic Acid as Treatment for Pre-Cirrhotic Fibrosis due to NASH
May 19, 2023 07:05AM Intercept Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to Review Obeticholic Acid as a Treatment for Pre-Cirrhotic Fibrosis due to NASH
May 16, 2023 05:00PM Intercept Pharma (ICPT) Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
May 16, 2023 05:00PM Intercept Pharmaceuticals Receives FDA Orphan Drug Designation for the Fixed-Dose Combination of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis (PBC)
Apr 27, 2023 07:00AM Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
Apr 27, 2023 06:55AM Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development
Apr 13, 2023 08:00AM Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023   
Mar 10, 2023 09:08AM Intercept Pharma (ICPT) Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Mar 10, 2023 09:05AM Intercept Announces FDA Advisory Committee Meeting Date for Obeticholic Acid as a Treatment for Pre-Cirrhotic Liver Fibrosis due to NASH
Mar 9, 2023 08:00AM Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Barclays Global Healthcare Conference March 14, 2023
Mar 2, 2023 07:00AM Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance
Feb 27, 2023 08:00AM Intercept Pharmaceuticals to Participate in Cowen’s 43rd Annual Health Care Conference on March 7, 2023 
Feb 23, 2023 08:00AM Intercept to Announce Fourth Quarter and Full Year 2022 Financial Results on March 2, 2023
Jan 19, 2023 08:00AM FDA Accepts Intercept’s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to NASH
Jan 5, 2023 08:00AM Intercept Pharmaceuticals to Present at J.P. Morgan 41st Annual Healthcare Conference on January 12, 2023
Jan 4, 2023 09:02AM Intercept Pharma (ICPT) Reports Efficacy and Safety Data from Phase 3 REGENERATE Study
Jan 4, 2023 09:00AM Intercept Announces Efficacy and Safety Data from Phase 3 REGENERATE Study in Liver Fibrosis due to NASH to be Presented at NASH-TAG Conference 2023
Dec 23, 2022 07:52AM Intercept Pharma (ICPT) Resubmits NDA to FDA for Obeticholic Acid in Patients with Liver Fibrosis cause by NASH
Dec 23, 2022 07:50AM Intercept Resubmits New Drug Application to U.S. FDA for Obeticholic Acid in Patients with Liver Fibrosis due to NASH
Dec 8, 2022 06:00PM New Study Published in The American Journal of Pathology Suggests Obeticholic Acid (OCA) May Improve Cognitive Impairment Associated with Cholestatic Liver Disease
Nov 22, 2022 08:00AM Intercept Pharmaceuticals to Participate in Piper Sandler’s 34th Annual Healthcare Conference on December 1, 2022 
Nov 7, 2022 06:55PM Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis
Nov 7, 2022 08:03AM Intercept Pharma (ICPT) Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study
Nov 7, 2022 08:00AM Intercept Announces Additional Positive Data in Fibrosis due to NASH from New Analysis of Phase 3 REGENERATE Study at AASLD The Liver Meeting® 2022
Nov 7, 2022 05:40AM Intercept Pharma (ICPT) Reports Two Analyses Demonstrating Improvement for PBC Patients Treated with OCA
Nov 6, 2022 08:00AM Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022
Nov 1, 2022 07:00AM Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update
Oct 31, 2022 04:05PM Intercept Announces New Data to be Presented in PBC, Liver Fibrosis due to NASH and Pipeline at AASLD The Liver Meeting® 2022
Oct 25, 2022 08:00AM Intercept to Announce Third Quarter 2022 Financial Results on November 1, 2022
Oct 12, 2022 08:00AM Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022
Sep 30, 2022 07:55AM Intercept Pharma (ICPT) Announces REVERSE Phase 3 Study of OCA in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Sep 30, 2022 07:55AM Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid (OCA) in Compensated Cirrhosis due to NASH Did Not Meet its Primary Endpoint
Sep 21, 2022 07:31AM Intercept Pharma (ICPT) Announces Summary of Key Actions in Strategic Financial Repositioning
Sep 21, 2022 07:30AM Intercept Pharmaceuticals Announces Summary of Key Actions in Strategic Financial Repositioning
Sep 20, 2022 12:45PM Intercept Pharma (ICPT) Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
Sep 20, 2022 12:45PM Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology
Sep 7, 2022 08:00AM Intercept Pharmaceuticals to Conduct Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences
Aug 29, 2022 08:00AM Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
View More Recent Stories View Older Stories